Pure Bioscience (OTCMKTS:PURE) Stock Price Passes Above Two Hundred Day Moving Average of $0.35

Share on StockTwits

Shares of Pure Bioscience, Inc. (OTCMKTS:PURE) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.35 and traded as high as $0.26. Pure Bioscience shares last traded at $0.23, with a volume of 67,585 shares.

The firm’s 50 day simple moving average is $0.28 and its 200 day simple moving average is $0.35.

In related news, Director Dale Okuno purchased 862,068 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were acquired at an average price of $0.29 per share, for a total transaction of $249,999.72. 44.18% of the stock is owned by insiders.

About Pure Bioscience (OTCMKTS:PURE)

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds.

Further Reading: How Investors Use a Balance Sheet

Receive News & Ratings for Pure Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pure Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stakinglab Price Reaches $0.46 on Top Exchanges
Stakinglab Price Reaches $0.46 on Top Exchanges
ShipChain  Hits One Day Volume of $5.00
ShipChain Hits One Day Volume of $5.00
Everex Hits One Day Volume of $1.98 Million
Everex Hits One Day Volume of $1.98 Million
Highwoods Properties Inc  Sees Large Increase in Short Interest
Highwoods Properties Inc Sees Large Increase in Short Interest
Equities Analysts Issue Forecasts for AVEO Pharmaceuticals, Inc.’s FY2021 Earnings
Equities Analysts Issue Forecasts for AVEO Pharmaceuticals, Inc.’s FY2021 Earnings
ESSA Pharma Inc  Sees Large Growth in Short Interest
ESSA Pharma Inc Sees Large Growth in Short Interest


 
© 2006-2019 Zolmax.